The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Radiopharmaceutical Market Research Report 2024
Synopsis
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceutical market was valued at US$ 6761 million in 2023 and is anticipated to reach US$ 11660 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical.
Report Scope
The Radiopharmaceutical market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceutical market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceutical manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceutical in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceutical market was valued at US$ 6761 million in 2023 and is anticipated to reach US$ 11660 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical.
Report Scope
The Radiopharmaceutical market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceutical market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceutical manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceutical in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Radiopharmaceutical Market Overview
1.1 Product Overview and Scope of Radiopharmaceutical
1.2 Radiopharmaceutical Segment by Type
1.2.1 Global Radiopharmaceutical Market Value Comparison by Type (2024-2030)
1.2.2 Actinium-225
1.2.3 Lutetium-177
1.2.4 Radium-223
1.2.5 Holmium-166
1.2.6 Other
1.3 Radiopharmaceutical Segment by Application
1.3.1 Global Radiopharmaceutical Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Radiopharmaceutical Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceutical Revenue 2019-2030
1.4.2 Global Radiopharmaceutical Sales 2019-2030
1.4.3 Global Radiopharmaceutical Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Radiopharmaceutical Market Competition by Manufacturers
2.1 Global Radiopharmaceutical Sales Market Share by Manufacturers (2019-2024)
2.2 Global Radiopharmaceutical Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Radiopharmaceutical Average Price by Manufacturers (2019-2024)
2.4 Global Radiopharmaceutical Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Radiopharmaceutical, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Radiopharmaceutical, Product Type & Application
2.7 Radiopharmaceutical Market Competitive Situation and Trends
2.7.1 Radiopharmaceutical Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Radiopharmaceutical Players Market Share by Revenue
2.7.3 Global Radiopharmaceutical Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Radiopharmaceutical Retrospective Market Scenario by Region
3.1 Global Radiopharmaceutical Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Radiopharmaceutical Global Radiopharmaceutical Sales by Region: 2019-2030
3.2.1 Global Radiopharmaceutical Sales by Region: 2019-2024
3.2.2 Global Radiopharmaceutical Sales by Region: 2025-2030
3.3 Global Radiopharmaceutical Global Radiopharmaceutical Revenue by Region: 2019-2030
3.3.1 Global Radiopharmaceutical Revenue by Region: 2019-2024
3.3.2 Global Radiopharmaceutical Revenue by Region: 2025-2030
3.4 North America Radiopharmaceutical Market Facts & Figures by Country
3.4.1 North America Radiopharmaceutical Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Radiopharmaceutical Sales by Country (2019-2030)
3.4.3 North America Radiopharmaceutical Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Radiopharmaceutical Market Facts & Figures by Country
3.5.1 Europe Radiopharmaceutical Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Radiopharmaceutical Sales by Country (2019-2030)
3.5.3 Europe Radiopharmaceutical Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radiopharmaceutical Market Facts & Figures by Country
3.6.1 Asia Pacific Radiopharmaceutical Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Radiopharmaceutical Sales by Country (2019-2030)
3.6.3 Asia Pacific Radiopharmaceutical Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Radiopharmaceutical Market Facts & Figures by Country
3.7.1 Latin America Radiopharmaceutical Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Radiopharmaceutical Sales by Country (2019-2030)
3.7.3 Latin America Radiopharmaceutical Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Radiopharmaceutical Market Facts & Figures by Country
3.8.1 Middle East and Africa Radiopharmaceutical Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Radiopharmaceutical Sales by Country (2019-2030)
3.8.3 Middle East and Africa Radiopharmaceutical Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Radiopharmaceutical Sales by Type (2019-2030)
4.1.1 Global Radiopharmaceutical Sales by Type (2019-2024)
4.1.2 Global Radiopharmaceutical Sales by Type (2025-2030)
4.1.3 Global Radiopharmaceutical Sales Market Share by Type (2019-2030)
4.2 Global Radiopharmaceutical Revenue by Type (2019-2030)
4.2.1 Global Radiopharmaceutical Revenue by Type (2019-2024)
4.2.2 Global Radiopharmaceutical Revenue by Type (2025-2030)
4.2.3 Global Radiopharmaceutical Revenue Market Share by Type (2019-2030)
4.3 Global Radiopharmaceutical Price by Type (2019-2030)
5 Segment by Application
5.1 Global Radiopharmaceutical Sales by Application (2019-2030)
5.1.1 Global Radiopharmaceutical Sales by Application (2019-2024)
5.1.2 Global Radiopharmaceutical Sales by Application (2025-2030)
5.1.3 Global Radiopharmaceutical Sales Market Share by Application (2019-2030)
5.2 Global Radiopharmaceutical Revenue by Application (2019-2030)
5.2.1 Global Radiopharmaceutical Revenue by Application (2019-2024)
5.2.2 Global Radiopharmaceutical Revenue by Application (2025-2030)
5.2.3 Global Radiopharmaceutical Revenue Market Share by Application (2019-2030)
5.3 Global Radiopharmaceutical Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bracco Imaging
6.1.1 Bracco Imaging Corporation Information
6.1.2 Bracco Imaging Description and Business Overview
6.1.3 Bracco Imaging Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bracco Imaging Radiopharmaceutical Product Portfolio
6.1.5 Bracco Imaging Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Radiopharmaceutical Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Mallinckrodt
6.3.1 Mallinckrodt Corporation Information
6.3.2 Mallinckrodt Description and Business Overview
6.3.3 Mallinckrodt Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mallinckrodt Radiopharmaceutical Product Portfolio
6.3.5 Mallinckrodt Recent Developments/Updates
6.4 Nordion
6.4.1 Nordion Corporation Information
6.4.2 Nordion Description and Business Overview
6.4.3 Nordion Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Nordion Radiopharmaceutical Product Portfolio
6.4.5 Nordion Recent Developments/Updates
6.5 Triad Isotopes
6.5.1 Triad Isotopes Corporation Information
6.5.2 Triad Isotopes Description and Business Overview
6.5.3 Triad Isotopes Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Triad Isotopes Radiopharmaceutical Product Portfolio
6.5.5 Triad Isotopes Recent Developments/Updates
6.6 Lantheus
6.6.1 Lantheus Corporation Information
6.6.2 Lantheus Description and Business Overview
6.6.3 Lantheus Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Lantheus Radiopharmaceutical Product Portfolio
6.6.5 Lantheus Recent Developments/Updates
6.7 IBA Group
6.6.1 IBA Group Corporation Information
6.6.2 IBA Group Description and Business Overview
6.6.3 IBA Group Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.4.4 IBA Group Radiopharmaceutical Product Portfolio
6.7.5 IBA Group Recent Developments/Updates
6.8 GE Healthcare
6.8.1 GE Healthcare Corporation Information
6.8.2 GE Healthcare Description and Business Overview
6.8.3 GE Healthcare Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.8.4 GE Healthcare Radiopharmaceutical Product Portfolio
6.8.5 GE Healthcare Recent Developments/Updates
6.9 China Isotope & Radiation
6.9.1 China Isotope & Radiation Corporation Information
6.9.2 China Isotope & Radiation Description and Business Overview
6.9.3 China Isotope & Radiation Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.9.4 China Isotope & Radiation Radiopharmaceutical Product Portfolio
6.9.5 China Isotope & Radiation Recent Developments/Updates
6.10 Jubilant Pharma
6.10.1 Jubilant Pharma Corporation Information
6.10.2 Jubilant Pharma Description and Business Overview
6.10.3 Jubilant Pharma Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Jubilant Pharma Radiopharmaceutical Product Portfolio
6.10.5 Jubilant Pharma Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Corporation Information
6.11.2 Eli Lilly Radiopharmaceutical Description and Business Overview
6.11.3 Eli Lilly Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Eli Lilly Radiopharmaceutical Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
6.12 Advanced Accelerator Applications
6.12.1 Advanced Accelerator Applications Corporation Information
6.12.2 Advanced Accelerator Applications Radiopharmaceutical Description and Business Overview
6.12.3 Advanced Accelerator Applications Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Advanced Accelerator Applications Radiopharmaceutical Product Portfolio
6.12.5 Advanced Accelerator Applications Recent Developments/Updates
6.13 SIEMENS
6.13.1 SIEMENS Corporation Information
6.13.2 SIEMENS Radiopharmaceutical Description and Business Overview
6.13.3 SIEMENS Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.13.4 SIEMENS Radiopharmaceutical Product Portfolio
6.13.5 SIEMENS Recent Developments/Updates
6.14 Dongcheng
6.14.1 Dongcheng Corporation Information
6.14.2 Dongcheng Radiopharmaceutical Description and Business Overview
6.14.3 Dongcheng Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Dongcheng Radiopharmaceutical Product Portfolio
6.14.5 Dongcheng Recent Developments/Updates
6.15 Navidea
6.15.1 Navidea Corporation Information
6.15.2 Navidea Radiopharmaceutical Description and Business Overview
6.15.3 Navidea Radiopharmaceutical Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Navidea Radiopharmaceutical Product Portfolio
6.15.5 Navidea Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radiopharmaceutical Industry Chain Analysis
7.2 Radiopharmaceutical Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radiopharmaceutical Production Mode & Process
7.4 Radiopharmaceutical Sales and Marketing
7.4.1 Radiopharmaceutical Sales Channels
7.4.2 Radiopharmaceutical Distributors
7.5 Radiopharmaceutical Customers
8 Radiopharmaceutical Market Dynamics
8.1 Radiopharmaceutical Industry Trends
8.2 Radiopharmaceutical Market Drivers
8.3 Radiopharmaceutical Market Challenges
8.4 Radiopharmaceutical Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
